Glyoxylate Reductase/Hydroxypyruvate Reductase: A Novel Prognostic Marker for Hepatocellular Carcinoma Patients after Curative Resection | Zendy

Yinglian Pan | Zendy; Runzhou Ni | Zendy; Qingchun Deng | Zendy; Xiaodong Huang | Zendy; Yixin Zhang | Zendy; Cuihua Lu | Zendy; Feifei Li | Zendy; Da Huang | Zendy; Song He | Zendy; Buyou Chen | Zendy

Open Access

Glyoxylate Reductase/Hydroxypyruvate Reductase: A Novel Prognostic Marker for Hepatocellular Carcinoma Patients after Curative Resection

Author(s) -

Yinglian Pan,

Runzhou Ni,

Qingchun Deng,

Xiaodong Huang,

Yixin Zhang,

Cuihua Lu,

Feifei Li,

Da Huang,

Song He,

Buyou Chen

Publication year - 2013

Publication title -

pathobiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.941

H-Index - 53

eISSN - 1423-0291

pISSN - 1015-2008

DOI - 10.1159/000346476

Subject(s) - hepatocellular carcinoma , immunohistochemistry , 2 acetylaminofluorene , carcinoma , medicine , cancer research , biology , enzyme , biochemistry , microsome

Glyoxylate reductase/hydroxypyruvate reductase (GRHPR) is a key enzyme in the glyoxylate cycle. Its deficiency causes primary hyperoxaluria type 2. We first noticed that GRHPR was also lost in human hepatocellular carcinoma (HCC) and proliferative HCC cells. The aim of the present study was to investigate the potential clinical utility of GRHPR in HCC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research